Alladapt Immunotherapeutics Receives FDA Fast Track Designation for ADP101 for the Treatment of Mono- and Multi-Food Allergies
November 22, 2023 08:00 ET
|
Alladapt Immunotherapeutics Inc.
– Fast Track Designation accelerates ADP101's development path for the treatment of mono- and multi-food allergy – – Phase 1/2 Harmony data for ADP101 recently presented at the 2023 American College...
Alladapt Immunotherapeutics Presents Phase 1/2 Harmony Data Demonstrating Therapeutic Potential and Safety of ADP101 for the Treatment of Food Allergy at 2023 ACAAI Annual Meeting
November 09, 2023 11:00 ET
|
Alladapt Immunotherapeutics Inc.
– Results aligned with patient needs and clinical practice priorities – – Alladapt preparing for ADP101 Phase 3 study in 2024 – MENLO PARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Alladapt...
Alladapt Immunotherapeutics Announces Topline Pediatric Data from Phase 1/2 Harmony Study Evaluating ADP101 for the Treatment of Patients with Mono- and Multi-Food Allergy, as Presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress
June 13, 2023 07:00 ET
|
Alladapt Immunotherapeutics Inc.
-Results from primary analysis conducted in pediatric patients demonstrate dose-dependent and clinically meaningful responses in addition to a favorable safety and tolerability profile- -Harmony,...
Alladapt Announces Presentations at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2023
May 16, 2023 07:00 ET
|
Alladapt Immunotherapeutics Inc.
MENLO PARK, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
Alladapt Appoints Louise Peacock as Chief Regulatory Affairs and Quality Officer
May 01, 2023 07:00 ET
|
Alladapt Immunotherapeutics Inc.
MENLO PARK, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
Alladapt to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:00 ET
|
Alladapt Immunotherapeutics Inc.
MENLO PARK, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
Alladapt to Participate in Two Upcoming Investor Conferences
November 08, 2022 07:00 ET
|
Alladapt Immunotherapeutics Inc.
MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
Alladapt to Participate in Citi's 17th Annual BioPharma Conference
August 31, 2022 07:00 ET
|
Alladapt Immunotherapeutics Inc.
MENLO PARK, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
Alladapt Announces Loan Agreement with Hercules Capital
August 30, 2022 07:00 ET
|
Alladapt Immunotherapeutics Inc.
Access to term loan of up to $50 million supports clinical development of ADP101 through initiation of Phase 3 trial and completion of Alladapt’s manufacturing facility Recent oversubscribed $119...
Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing
June 22, 2022 07:00 ET
|
Alladapt Immunotherapeutics Inc.
Financing from new and existing investors will support continued development of a novel treatment for food allergy Jim Momtazee and George Montgomery to join Alladapt’s Board of Directors MENLO...